Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.
cholangiocarcinoma
epidemiology
liver
primary sclerosing cholangitis
risk factors
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
25
05
2021
accepted:
31
07
2021
pubmed:
18
9
2021
medline:
24
2
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
Cholangiocarcinoma (CCA) is a cancer arising from the intra- and extrahepatic bile ducts. The early stages are often asymptomatic, CCA is frequently diagnosed in an advanced stage and the prognosis of CCA is often dismal. Our objective was to estimate the incidence of CCA in Finland and to identify risk factors for CCA, with a special interest in primary sclerosing cholangitis (PSC). We identified all CCA cases during 1974-2018 from the Finnish Cancer Registry and calculated age-standardised incidence rates. Five controls for each case were extracted from the Population Registry, matched by age, gender and municipality of residence at the time of diagnosis. Odds ratios (ORs) for risk factors were estimated with conditional logistic regression and survival estimates with the Kaplan-Meier method. Incidence of CCA remained stable in both genders; the age-standardised rate (World Standard) in 2013-2017 in males and females was 1.7 per 100,000 person years and 1.3 per 100,000 person years, respectively. Primary sclerosing cholangitis carried a 30-fold risk of intrahepatic cholangiocarcinoma (iCCA) and 25-fold risk of extrahepatic cholangiocarcinoma (eCCA). Diabetes, inflammatory bowel disease and liver cirrhosis were associated with iCCA, whereas cholelithiasis and viral hepatitis C were associated with eCCA. The cumulative 5-year survival was 4.6%. The incidence of CCA has been stable. Known risk factors for CCA were confirmed, with PSC having the highest OR. Survival remains poor.
Sections du résumé
BACKGROUND
Cholangiocarcinoma (CCA) is a cancer arising from the intra- and extrahepatic bile ducts. The early stages are often asymptomatic, CCA is frequently diagnosed in an advanced stage and the prognosis of CCA is often dismal.
OBJECTIVE
Our objective was to estimate the incidence of CCA in Finland and to identify risk factors for CCA, with a special interest in primary sclerosing cholangitis (PSC).
METHODS
We identified all CCA cases during 1974-2018 from the Finnish Cancer Registry and calculated age-standardised incidence rates. Five controls for each case were extracted from the Population Registry, matched by age, gender and municipality of residence at the time of diagnosis. Odds ratios (ORs) for risk factors were estimated with conditional logistic regression and survival estimates with the Kaplan-Meier method.
RESULTS
Incidence of CCA remained stable in both genders; the age-standardised rate (World Standard) in 2013-2017 in males and females was 1.7 per 100,000 person years and 1.3 per 100,000 person years, respectively. Primary sclerosing cholangitis carried a 30-fold risk of intrahepatic cholangiocarcinoma (iCCA) and 25-fold risk of extrahepatic cholangiocarcinoma (eCCA). Diabetes, inflammatory bowel disease and liver cirrhosis were associated with iCCA, whereas cholelithiasis and viral hepatitis C were associated with eCCA. The cumulative 5-year survival was 4.6%.
CONCLUSIONS
The incidence of CCA has been stable. Known risk factors for CCA were confirmed, with PSC having the highest OR. Survival remains poor.
Identifiants
pubmed: 34533900
doi: 10.1002/ueg2.12154
pmc: PMC8672081
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1128-1135Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32
pubmed: 25966423
Liver Int. 2018 Mar;38(3):532-541
pubmed: 28796371
Cureus. 2019 Jan 25;11(1):e3962
pubmed: 30956914
United European Gastroenterol J. 2021 Dec;9(10):1128-1135
pubmed: 34533900
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):678-684
pubmed: 30633038
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Endoscopy. 2017 Jun;49(6):588-608
pubmed: 28420030
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
J Natl Cancer Inst. 2007 Jun 6;99(11):895-7
pubmed: 17551150
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70
pubmed: 18977670
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1051-8
pubmed: 22653260
Hepatology. 2010 Aug;52(2):571-7
pubmed: 20683956
Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8
pubmed: 17689296
J Natl Compr Canc Netw. 2018 Apr;16(4):370-376
pubmed: 29632056
Lancet. 2008 May 24;371(9626):1777-82
pubmed: 18502302
Liver Int. 2012 Feb;32(2):214-22
pubmed: 21745316
Gastroenterology. 2002 May;122(5):1500-11
pubmed: 11984534
Ann Hepatol. 2017 Jan-Feb 2017;16(1):133-139
pubmed: 28051802
Vaccine. 2017 Jan 11;35(3):412-418
pubmed: 28003042
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
J Hepatol. 2012 May;56(5):1181-1188
pubmed: 22245904
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2416-2422
pubmed: 31306801
Scand J Gastroenterol. 2020 Jan;55(1):74-81
pubmed: 31902255
J Hepatol. 2009 Jan;50(1):158-64
pubmed: 19012991
Liver Int. 2016 Nov;36(11):1563-1579
pubmed: 27276701
World J Gastrointest Oncol. 2010 Nov 15;2(11):407-16
pubmed: 21160904
Liver Int. 2012 Mar;32(3):441-8
pubmed: 22098097
Cancer. 2020 Jun 1;126(11):2666-2678
pubmed: 32129902
Surg Pathol Clin. 2018 Jun;11(2):403-429
pubmed: 29751883
JAMA. 2013 Jul 24;310(4):427-8
pubmed: 23917294
PLoS One. 2017 Oct 19;12(10):e0186643
pubmed: 29049401
Hepatology. 2013 Dec;58(6):2045-55
pubmed: 23775876
Clin Liver Dis. 2016 Feb;20(1):79-98
pubmed: 26593292
BMC Gastroenterol. 2017 Dec 8;17(1):149
pubmed: 29216833
Scand J Public Health. 2012 Aug;40(6):505-15
pubmed: 22899561